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Abstract 
 
The dihydropyridines (DHPs), nifedipine and nicardipine, modulate native glycine 
receptors (GlyRs) at micromolar concentrations. Nicardipine has a biphasic 
potentiating and inhibitory effect, whereas nifedipine causes inhibition only. The 
present study sought to investigate 1) the molecular mechanism by which these 
compounds inhibit recombinant GlyRs, and 2) their potential utility as subunit-
selective inhibitors of α1, α1β, α3 and α3β GlyRs. The rate of onset of inhibition in 
the open state was accelerated by pre-application of DHP in the closed state, with the 
degree of acceleration proportional to the concentration of pre-applied DHP. This 
implies a non-inhibitory binding site close to the DHP inhibitory site. DHP inhibition 
was use-dependent and independent of glycine concentration, consistent with a pore-
blocking mode of action. DHP sensitivity was abolished by the G2’A mutation, 
providing a strong case for DHP binding site deep in the pore. Nifedipine exhibited an 
approximately 10-fold higher inhibitory potency at α1-containing relative to α3-
containing receptors, whereas nicardipine was only weakly selective for α1-
containing GlyRs. The differential sensitivities of nifedipine and nicardipine for 
different GlyR isoforms suggest that DHPs may be a useful resource to screen as 
pharmacological tools for selectively inhibiting different synaptic GlyR isoforms. 
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Introduction 
 
Glycine receptors (GlyRs) mediate inhibitory neurotransmission in the adult rat 
spinal cord and brainstem (Lynch, 2004). They incorporate an anion-selective pore 
and are members of the pentameric Cys-loop family of ligand-gated ion channels. 
Individual subunits of the Cys-loop receptor family contain a large N-terminal ligand-
binding domain followed by a bundle of four transmembrane α-helical domains 
(Unwin, 2005). Each of the five subunits contributes its second transmembrane 
domain (M2) to the lining of the central water-filled pore. To date, five GlyR subunits 
have been identified (α1-α4, β). Embryonic receptors generally comprise α2 
homomers or α2β heteromers, whereas the dominant adult subtype is the 
α1β heteromer (Lynch, 2004). Heteromeric GlyRs are thought to exist in a 2α:3β 
stoichiometry (Grudzinska et al., 2005). The β subunit, which is widely distributed 
throughout the adult nervous system, mediates the anchoring of GlyRs to the 
cytoskeleton via a direct binding interaction with the cytoplasmic protein, gephyrin 
(Kim et al., 2006). The α1- α4 subunits exhibit differential central nervous system 
distribution patterns that are particularly evident in the superficial dorsal horn of the 
spinal cord (Harvey et al., 2004) and the retina (Haverkamp et al., 2003; Haverkamp 
et al., 2004; Heinze et al., 2007).  The physiological consequences of the differential 
distribution patterns are difficult to establish as there are currently few 
pharmacological probes that can selectively inhibit different β subunit-containing 
GlyR isoforms (Betz and Laube, 2006; Webb and Lynch, 2007). The identification of 
compounds that can pharmacologically discriminate between α1- and α3-containing 
GlyRs may help in understanding the role of α3 GlyRs in inflammatory pain 
processing in spinal nociceptive neurons (Ahmadi et al., 2002; Harvey et al., 2004; 
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Reinold et al., 2005; Zeilhofer, 2005) and in cone signal processing in the retina 
(Haverkamp et al., 2003).  
Dihydropyridines (DHPs) such as nifedipine (NF) and nicardipine (NC) are 
important for the treatment of hypertension, angina, atrial arrhythmia and myocardial 
ischaemia (Struyker-Boudier et al., 1990). These drugs act therapeutically by 
inhibiting calcium flux through L-type Ca2+ channels, thereby inducing the relaxation 
of vascular smooth muscle and the suppression of cardiac contractility. They inhibit 
L-type Ca2+ channels at nanomolar concentrations but inhibit other Ca2+ channels at 
micromolar concentrations (Struyker-Boudier et al., 1990; Dunlap et al., 1995). Low 
micromolar concentrations of NF and NC have also been shown to modulate native 
GlyRs in cultured ventral spinal cord neurons (Chesnoy-Marchais and Cathala, 2001). 
These effects were selective for GlyRs over GABAA receptors in the same cells. 
In the present study, we examined whether NF and NC may be useful as subunit-
selective inhibitors of the α1, α1β, α3 and α3β GlyRs. The results suggest that NF 
may have a reasonable degree of selectivity for α1-containing GlyRs over α3-
containing GlyRs. In addition, we have identified a molecular determinant of the 
inhibitory effect of these compounds. 
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Materials and Methods 
 
Mutagenesis and expression of GlyR cDNAs 
The human GlyR α1, rat α3L and human β subunit cDNAs were subcloned into 
the pCIS, pcDNA3.1 and pIRES2-EGFP plasmid vectors, respectively. Site-directed 
mutagenesis was performed using the QuickChange mutagenesis kit (Stratagene, La 
Jolla, CA, USA) and the successful incorporation of mutations was confirmed by 
DNA sequencing. A chimera of the α3 subunit was created whereby the α3 M4 
domain residues, A401 – D431, were replaced by the corresponding residues (I393 – 
Q421) of the α1 M4 domain. This chimera was generated according to the “seamless” 
protocol (Padgett and Sorge, 1996). Briefly, long PCR of the vector encoding α3L 
was performed with primers incorporating EarI sites at the termini and this fragment 
was ligated to a PCR fragment of α1 M4 incorporating compatible EarI sites at each 
termini. The final construct was confirmed by DNA sequencing.  
HEK293 cells, cultured in Dulbecco’s Modified Eagles Medium, were transfected 
using a calcium phosphate precipitation protocol. When co-transfecting GlyR α and β 
subunit constructs, the respective plasmid DNAs were combined in a ratio of 1:10. 
After exposure to transfection solution for 24 hrs, cells were washed twice using 
calcium-free phosphate buffered saline, then returned to standard culture medium and 
used for recording over the following 24 - 72 hrs.  
 
Electrophysiology  
The cells were viewed via an inverted fluorescent microscope and currents were 
recorded in the whole-cell patch-clamp configuration. Cells were superfused by a 
control solution containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 
10 glucose, with the pH adjusted to 7.4 with NaOH. Patch pipettes were fabricated 
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from borosilicate hematocrit tubing (Vitrex, Modulohm, Denmark) and heat polished. 
Pipettes had a tip resistance of 1 - 2 MΩ when filled with the standard pipette solution 
containing (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES, 10 EGTA, with the pH 
adjusted to 7.4 with NaOH. After establishment of the whole-cell configuration, cells 
were voltage-clamped at –40 mV (unless otherwise indicated) and membrane currents 
were recorded using an Axopatch 1D amplifier and pCLAMP9 software (Axon 
Instruments, Union City, CA, USA). The cells were perfused by a parallel array of 
microtubular barrels through which solutions were gravity-induced. This system 
permitted complete solution exchange within 100 ms. Experiments were conducted at 
room temperature (19 – 22oC).  
Because α homomers can form functional GlyRs, it is necessary to confirm the 
incorporation of β subunits into functional αβ heteromers. As the GlyR β subunit 
cDNA was cloned into the pIRES2-EGFP plasmid vector, we used GFP fluorescence 
to identify cells expressing the GlyR β subunit. The successful incorporation of β 
subunits into functional receptors was also inferred by their characteristic reduction in 
picrotoxin (PTX) sensitivity (Pribilla et al., 1992; Handford et al., 1996) as 
demonstrated in Fig. 1. 
PTX, picrotoxinin (PTXININ), NF and NC were all obtained from Sigma (St 
Louis, MO, USA) and stored frozen as 50 mM stocks in dimethylsulfoxide.  
 
Data Analysis  
Results are expressed as mean ± standard error of the mean of three or more 
independent experiments. The Hill equation was used to calculate the half-maximal 
concentration (EC50) and Hill coefficient (nH) values for glycine activation. A similar 
equation was also used to calculate the half maximal concentrations for inhibition 
(IC50) and nH values of the antagonists tested in this study. All curves were fitted 
   
 7 
using a non-linear least squares algorithm (Sigmaplot 9.0, Jandel Scientific, San 
Rafael, CA, USA). Statistical significance was determined by paired or unpaired 
Student’s t-test, as appropriate, with P < 0.05 representing significance. One-way 
ANOVA (GraphPad Prism, Version 4 for Windows, GraphPad Software, Inc., San 
Diego, CA, USA) was used for the comparison of means of more than three groups. 
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Results 
 
Expression and functional properties of GlyR isoforms 
Examples of the response of cells expressing α3 and α3β GlyRs to increasing 
concentrations of glycine are shown in Fig. 1A. Glycine concentration-responses, 
averaged from at least three cells expressing the α1, α1β, α3 and α3β GlyRs, are 
presented in Fig. 1B with the mean EC50 and nH values of best fit presented in Table 
1. This table also includes the averaged EC50 and nH values for all mutant GlyRs 
examined in this study. The EC50 values for the α3 and α3β GlyRs are several fold 
higher than previously reported by others (Meier et al., 2005; Miller et al., 2005). The 
reasons for this are unknown. However, similar results are consistently observed in 
our laboratory (Yang et al., 2007). The incorporation of β subunits into functional 
GlyRs results in a characteristic reduction in receptor sensitivity to PTX (Pribilla et 
al., 1992; Handford et al., 1996). To confirm the successful incorporation of β 
subunits into functional GlyRs, the effects of 10 µM PTX on currents activated by an 
EC50 (30 µM) glycine concentration were compared at the α1 and α1β GlyRs. The 
averaged results confirm the expected reduction in PTX sensitivity in the α1β GlyR 
(Fig. 1D).  We have recently demonstrated that PTXININ is better than PTX at 
pharmacologically discriminating between α3  homomeric and α3β heteromeric 
GlyRs (Yang et al., 2007). We therefore compared the inhibitory potency of 1 µM 
PTXININ on currents activated by EC50 (300 µM) glycine at the α3 and α3β GlyRs 
(e.g., Fig. 1C). The percentage of original current remaining in 1 µM PTXININ, 
averaged from four cells expressing each receptor, is presented in Fig. 1D. These 
results confirm that co-expression of α1 or α3 together with the β subunit results in 
the formation of heteromeric receptors.  
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Mechanism of DHP action 
As described below (Fig. 5), NF and NC exhibited no direct effect in the absence 
of glycine. In addition to its inhibitory effect, NC has also been reported to potentiate 
currents activated by sub-saturating glycine concentrations (Chesnoy-Marchais and 
Cathala, 2001). We also found that NC exerts a dual potentiating and inhibitory effect 
on α1 and α1β GlyRs. For homomeric α1 GlyRs, potentiation was observed only at 
glycine concentrations less than EC30. However, in many cells the NC potentiating 
response was labile, either disappearing completely or progressively declining in 
magnitude over time (data not shown). NC produced only inhibition of α3 and α3β 
GlyRs, regardless of the glycine concentration used (e.g., Fig. 6A, below). The onset 
of potentiation of α1 GlyRs by NC was faster than that of inhibition, as shown by the 
biphasic response to increasing concentrations of NC in the presence of EC20 (20 µM) 
glycine (Fig. 2A, upper panel). The potentiating concentration-response, averaged 
from 11 cells (Fig. 2B), was bell-shaped with a peak at around 30 µM, possibly due to 
truncation of the potentiation peak by a faster onset of inhibition at higher NC 
concentrations. Examples of inhibition by NC of currents activated by EC50 (30 µM) 
glycine in homomeric α1 GlyRs are shown in Fig. 2A (lower panel), with averaged 
concentration-responses presented in Fig. 2B.  The averaged IC50 and nH values for 
NC inhibition are given in Table 2. Examples of the inhibitory effects of NF on 
currents activated by EC50 glycine at the α1 GlyR are shown in Fig. 2C and the 
averaged inhibitory concentration-response is plotted in Fig. 2D. The averaged 
parameters of best fit to the inhibitory concentration-response are given in Table 2. 
We next investigated whether DHP inhibition was dependent of glycine 
concentration. In this experiment, the inhibitory potencies of NF (10 µM) and NC (30 
µM) were compared at EC20, EC50 and saturating glycine concentrations on 
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homomeric α1and α3 GlyRs, respectively. As indicated in Fig. 3A, inhibition by both 
NF and NC is glycine-independent. 
To investigate voltage-dependence, we activated homomeric α1 GlyRs with an 
EC50 glycine concentration and compared the percentage inhibition induced by NF 
(10 µM) or NC (30 µM) at -80, -20 and +40 mV. The pooled results, summarised in 
Fig. 3B, reveal that the inhibition by both compounds is not significantly voltage-
dependent. Such a result is expected given that both compounds are uncharged. 
While the above experiments quantified the effects of extracellularly applied 
DHPs, we also sought to determine whether NF could access a binding site from the 
intracellular membrane surface. With 100 µM NF in the patch pipette, we found that 
the magnitude of whole-cell α1 GlyR current did not change significantly during the 
first 10 min of whole-cell recording (n = 3 cells, data not shown), and that currents 
with magnitudes > 10 nA were invariably observed. We therefore conclude that DHPs 
access their site from the extracellular membrane surface only. This agrees with the 
results of a similar experiment performed on native spinal neuronal GlyRs (Chesnoy-
Marchais and Cathala, 2001). 
We then investigated the use-dependence of NF and NC at homomeric α1 GlyRs 
as shown in Fig. 4A. First, a saturating (2 mM) glycine concentration was applied to 
cells, then the time course of onset of the inhibitory response to 10 µM NF was 
determined (Fig. 4A, left panel). NF was then pre-applied for 10 s in the absence of 
glycine, then glycine plus NF were co-applied (second panel). The large magnitude of 
the initial glycine-induced current spike indicates that NF applied in the closed state 
does not inhibit GlyRs as efficiently as when applied in the open state, indicating that 
the inhibition is use-dependent. Surprisingly, however, the rate of onset of NF 
inhibition in the open state was accelerated by the pre-application of NF in the closed 
state. We next pre-applied NF in the closed state, and then simultaneously removed 
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NF while applying glycine (Fig. 4A, third panel). Following activation of the 
channels, the onset of the NF inhibitory response followed exactly the same time 
course as when glycine was applied in the continued presence of NF, as in panel 2. 
However, as expected in the absence of NF, this inhibition was not sustained and the 
recovery from inhibition occurred at around the same rate as seen in the first panel. 
This result strongly suggests that NF is able to associate closely with the GlyR in the 
closed state without efficiently inhibiting the current, implying the existence of a 
separate site to which NF can bind in the closed state without producing inhibition. It 
is only when the GlyR is activated that NF can reach its inhibitory binding site. We 
term these sites the ‘non-inhibiting’ and ‘inhibiting’ sites, respectively. Panel 4 in Fig. 
4A is a control showing that the simultaneous co-application of glycine plus NF 
produces a slower onset of inhibition similar to that seen in panel 1. To show this 
more clearly, the time course of the onset of inhibition by NF under each of the four 
experimental conditions (labelled 1 – 4 in Fig. 4A) are shown normalised on an 
expanded time scale in Fig. 4B. These curves were adequately fit with single 
exponentials (not shown) and the respective time constants averaged from three cells 
subject to the same experimental procedure are summarised in Fig. 4C. A similar 
pattern of activity was observed with NC as summarised in Fig. 4D. 
To investigate the functional properties of the non-inhibiting site, we performed 
two sets of experiments that are summarised in Fig. 5. In an attempt to quantitate the 
NF sensitivity of the non-inhibiting site, we applied increasing concentrations of NF 
for 30 s periods and determined the time constant of inhibition onset when 2 mM 
glycine was subsequently applied. A sample experiment, which also included regular 
control glycine applications, is shown in Fig. 5A. The time courses of the onset of 
current inhibition under each of the indicated NF concentrations (labelled 1 – 5) are 
shown normalised on an expanded time scale in Fig. 5B. This panel also shows that 
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30 and 60 s applications of 0.3 µM NF have no measurably different effect on the rate 
or magnitude of inhibition, thus indicating that NF had equilibrated with a non-
inhibiting binding site within 30 s under the conditions employed in this experiment. 
The curves in Fig. 5B were adequately fit with single exponentials and the time 
constants averaged from four cells are summarised in Fig. 5C. When plotted against 
concentration on a semi-log plot, the time constants were well fitted by a linear 
regression. These data clearly show that the rate of onset of the inhibition is 
dependent on the concentration of pre-applied NF. As discussed in detail below, this 
result is not consistent with a single non-inhibiting DHP site per receptor. It is more 
consistent with a ‘reservoir’ that can accommodate a number of DHP molecules in 
proportion to the free external DHP concentration.  
Fig. 5D plots the averaged peak currents (triangles) and averaged minimum 
currents (circles) as a function of NF concentration. The averaged NF inhibitory 
concentration-response measured in the presence of glycine (reproduced from Fig. 
2D) is included as a dashed line for comparison. That the circles provide a 
surprisingly good fit to the dashed line indicates that a given concentration of NF 
applied in the closed state causes the same degree of inhibition as when the same 
concentration of NF is applied in the open state. In other words, the NF molecules in 
free solution and NF molecules that bind to the non-inhibiting site both seem to create 
a similar NF concentration at the inhibiting site when the channels are opened. Rather 
less can be inferred from the concentration-dependence of peak current magnitude 
(triangles in Fig. 5D). The decline in peak current magnitude seen at higher NF 
concentrations is a consequence of the faster onset of inhibition relative to the rate of 
channel opening which is limited by the solution exchange rate.  
We next sought to determine the reversibility of NF binding at the non-inhibiting 
site and to compare the NF dissociation rates from the non-inhibiting and inhibiting 
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sites. To address these questions, we applied a 10 µM concentration of NF for 30 s, 
then waited a varying period of time (0, 2, 5 and 30 s) before adding 2 mM glycine. A 
sample experiment, which includes regular glycine-only controls, is shown in Fig 5E. 
The time courses of inhibition onset in response to each of the indicated NF 
concentrations (labelled I – IV) are shown normalised on an expanded time scale in 
Fig. 5F. Two controls (both labelled V) recorded in the absence of a prior NF 
application are also included but are superimposed in Fig. 5F. Time constants of best 
fit to these curves, averaged from three cells, are summarised in Fig. 5G. The same 
results are also shown normalised to the maximum time constants recorded in the 
same cell (Fig. 5H). It is apparent that the half recovery time lies between 5 and 30 s. 
By interpolating between these values using sigmoidal curve fits to the data from each 
cell, we estimated a mean half recovery time of 9.7 ± 2.2 s (n = 3). This result 
provides a measure of the time course with which NF unbinds from the non-inhibiting 
site in the closed state. The mean half recovery time from the inhibiting site, measured 
directly from the 0 s trace in the same three cells, was 7.9 ± 1.1 s (n = 3). These values 
are not significantly different, possibly suggesting that NF dissociation from the non-
inhibiting site controls the rate at which it dissociates from the inhibiting site as well. 
 
Subunit selectivity 
The steady-state inhibitory concentration-responses of NC and NF at the α1, α3, 
α1β and α3β GlyRs were measured in the presence of an EC50 glycine concentration. 
The glycine concentrations used in these experiments are listed in Table 2. Sample 
experiments are displayed in Fig. 6A. The averaged concentration-responses for NF at 
each of the four GlyR subtypes are displayed in Fig. 6B. All averaged IC50 and nH 
values of best fit are presented in Table 2. The results indicate that homomeric α1 
GlyRs are significantly more sensitive than homomeric α3 GlyRs to inhibition by NF. 
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They also show that incorporation of the β subunit produces an increased NF 
sensitivity. This increase was not statistically significant for heteromeric α1β GlyRs, 
but was significant (P < 0.05, Student’s unpaired t-test) for α3β GlyRs. A similar 
pattern was seen with NC. The averaged concentration-responses for NC at each of 
the four GlyR subtypes are displayed in Fig. 6C, with parameters of best fit 
summarised in Table 2.  These results suggest that NF could be useful for 
pharmacologically discriminating α1- from α3-containing GlyRs. 
 
Molecular determinants of DHP inhibition 
As use-dependence and non-competitive inhibition are characteristic of open 
channel blockers, we investigated whether DHPs bind in the pore. As indicated in the 
M2 domain sequence alignment (Fig. 7A), the pore-lining domains of the α1 and α3 
subunits differ only in the identity of the 2’ pore-lining residue, whereas the β subunit 
displays a low sequence homology throughout most of its length. Non-conserved 
residues at the 2’ and 6’ positions are thought to provide the binding site for PTX 
(Zhorov and Bregestovski, 2000; Shan et al., 2001; Yang et al., 2007) and ginkgolides 
(Kondratskaya et al., 2005; Hawthorne et al., 2006; Heads et al., 2008) and possibly 
also to cyanotriphenylborate (Rundstrom et al., 1994) and butyrolactones (Steinbach 
et al., 2000). Indeed, a DHP binding site at the 6’ position was predicted on the basis 
of a structural comparison of the GlyR pore with the L-type calcium channel DHP 
binding site (Chesnoy-Marchais and Cathala, 2001). Given these considerations, we 
investigated the possibility that DHPs might also bind in the 2’ – 6’ region and that 
the differential sensitivity of NF for α1 and α3 GlyRs might be explained by the non-
conserved residue at the 2’ position. We further hypothesised that the effect of the β 
subunit on NF sensitivity may be mediated by the amino acid differences at the 2’ 
and/or 6’ positions. 
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We therefore measured the NF and NC inhibitory concentration-responses at the 
α1G2’A, α1G2’P and α1G2’Aβ GlyRs. Due to the low sensitivities of the α1G2’A and 
α1G2’P GlyRs to both NF and NC, it was not possible to generate full inhibitory 
concentration-response curves. However, it was evident that the IC50 values for both 
compounds were > 100 µM (Table 2). Fig. 7B shows the averaged inhibitory 
concentration-responses for NF and NC at the α1β, α3β and α1G2’Aβ GlyRs, with the 
mean parameters of best fit summarised in Table 2. The low NF sensitivity of the α3β 
GlyR can be transferred to the α1β GlyR via the α1 subunit G2’A mutation. Thus, the 
2’ residue appears to be a specific determinant of DHP sensitivity. However, because 
the homomeric α1G2’A GlyR has a lower DHP sensitivity than either the homomeric 
α1 or α3 GlyRs (Table 2), it is likely that other differences between the α3 and 
α1 GlyR also contribute to DHP sensitivity. The sensitivity of homomeric α1 GlyRs 
to NC is also abolished by the α1G2’A mutation (Fig. 7B, Table 2).   
The role of the α1 subunit 6’ residue in mediating the subunit-specific effects of 
NF and NC was investigated by measuring IC50 values at the α1T6’F GlyR (the α to β 
subunit substitution) and at the more conservative α1T6’A and α1T6’S GlyRs. As shown 
in Fig. 7C and summarised in Table 2, the averaged NF and NC IC50 values were not 
significantly changed by any of these mutations. Threonine residues can participate in 
hydrogen bonds via their hydroxyl groups and hydrophobic interactions via their 
methyl groups. To investigate more specifically possible hydrogen bonding with 6’ 
threonines, we also examined the effect of the T6’V mutation, which replaces the OH 
with a methyl group. As this mutation also had no significant effect on receptor 
sensitivity to either NF or NC (Fig 7C and Table 2), we conclude that 6’ threonines 
are not important for interactions with DHPs, by either hydrogen bonds or 
hydrophobic interactions.  
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As discussed below, our functional data (as summarised in Figs. 4 and 5) suggest 
that DHP may bind to a site in or near the external surface of the lipid bilayer. In an 
attempt to identify this site, we took advantage of the fact that α1 and α3 subunits are 
differentially sensitive to NF and hypothesised that non-conserved residues in the 
transmembrane or adjacent extracellular domains may mediate this differential 
sensitivity. With the exception of M4 and the C-terminal tail, the amino acid 
sequences of the α1 and α3 subunits are highly conserved throughout all 
transmembrane and adjacent external domains. A sequence alignment of the M4 and 
C terminal tail (Fig. 8) reveals a total of ten non-conserved residues, many of which 
are reactive. The C-terminal tail of the α3 subunit also contains two additional 
residues relative to the α1 subunit. To determine whether this region mediates the 
differential sensitivity to NF, we made a chimera of α3 and α1 subunits (termed α3α1-
M4) where residues A401 – D431 of the α3 M4 domain were replaced by the 
corresponding residues I393 – Q421 of the α1 subunit. We also mutated to alanines 
each of the α1 residues shown as shaded in Fig. 8, and deleted the final two residues 
of the α3 subunit. The tested constructs were as follows: α1I393A/G394A (double 
mutant), α1M397A, α1M404A, α1R415A, α1H419A (which is conserved but reactive), 
α1N420A and α3Q430Δ/D431Δ (double deletion). The mean glycine EC50 and nH values for 
all these constructs are summarised in Table 1. Each construct was investigated by 
quantitating the percentage inhibition produced by 10 µM NF of currents activated by 
the respective EC50 glycine concentration as given in Table 3. As summarised in 
Table 3, the α3α1-M4 and α3 GlyRs exhibited similar NF sensitivities, thus eliminating 
this domain as a determinant of the differential NF sensitivity. Furthermore, the 
results obtained using the other M4 mutant α1 GlyRs provide no evidence that non-
conserved M4 residues form the NF binding site. An interesting outcome of these 
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experiments is that the high glycine sensitivity of the α3α1-M4 chimera implies a role 
for the M4 domain in GlyR gating. 
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Discussion 
 
Location of the inhibitory site 
An unusual feature is that while pre-incubation with DHP does not directly inhibit 
glycine-activated currents, DHP pre-incubation increases the subsequent rate of 
inhibition. This indicates the presence of both inhibiting and non-inhibiting sites, with 
only the non-inhibiting site being accessible in the closed state. Binding to the non-
inhibiting site enhances access to the inhibiting site when channels are opened. This 
discussion will consider the locations of both sites, starting with the inhibiting site. 
Our data do not differentiate between desensitisation, allosteric inhibition or direct 
block as possible mechanisms of DHP inhibition. However, two lines of evidence 
strongly suggest that DHPs bind in the channel pore. First, functional data indicate 
that DHP inhibition is use-dependent and independent of glycine concentration, both 
classical characteristics of open channel blockers. Second, the relatively conservative 
α1G2’A mutation caused a dramatic loss in DHP inhibitory potency, suggesting this 
mutation ablated a pore binding site. However, the α3 GlyR, which shares an 
identical M2 domain amino acid sequence with the α1G2’A GlyR, retained weak 
sensitivity to DHP inhibition suggesting that other domains of the GlyR also 
contribute to the DHP sensitivity differences between α1 and α3 GlyRs.  
The original hypothesis proposed that DHPs were coordinated by 6’ threonines 
(Chesnoy-Marchais and Cathala, 2001). However, our results indicate that DHP 
inhibition is insensitive to 6’ mutations. Threonines can contribute to both hydrogen 
bonds and hydrophobic interactions. However, selective elimination of their 
hydrophobic interaction capability by the T6’S mutation, and of their hydrogen 
bonding capability by the T6’V mutation, and of both binding capabilities by the 
   
 19 
T6’A mutation, had minimal effects on DHP inhibitory potency. These results are 
incompatible with a direct binding interaction between DHPs and 6’ Thr residues.  
Molecular docking studies, performed as described in Hawthorne et al. (2006), 
established the feasibility of DHP block of GlyRs at the 2’ level in the pore (not 
shown). However, due to uncertainties associated with the homology model and our 
poor understanding of the nature of conformational changes associated with channel 
activation, this model cannot be considered reliable predictor of the specific details of 
binding. 
Based on all these considerations, we conclude that DHPs most likely bind at the 
2’ pore-lining position, where they are coordinated primarily by backbone groups near 
the 2’ level. 
 
The non-inhibiting site 
Let us first consider the possibility of a single non-inhibiting DHP site per 
receptor. In this scenario, the number of channels that have DHP bound at a single 
non-inhibiting site will increase with concentration, and this will be reflected by an 
increased magnitude of inhibition when the channels are opened. However, the rate of 
DHP transition from the non-inhibiting site to the inhibiting site should be 
concentration-independent as the required proximity of the two sites would demand 
that the effective local concentration be either very high or zero. This model is 
inconsistent with our data because the rate of DHP inhibition depends on the 
concentration of DHP at the non-inhibiting site. 
Our results are more consistent with a non-inhibiting ‘site’  or 'reservoir' that can 
simultaneously accommodate multiple DHP molecules with an occupancy rate 
proportional to the DHP concentration in the external solution. Such a model would 
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explain our observation (Fig. 6B and C) that the rate of DHP inhibition is proportional 
to the DHP concentration in the external solution.  
The cell membrane is one candidate for this site as DHPs are known to partition 
into the lipid bilayer and concentrate at the lipid-water interface (Herbette et al., 1989; 
Mason et al., 1992; Herbette et al., 1994). However, for a direct transition to occur 
between the non-inhibiting and inhibiting sites, they need to be closely located. It is 
difficult to conceive how DHPs at the external lipid-water interface could more 
efficiently access an inhibitory site located deep in the pore than DHPs in free 
aqueous solution. Alternatively a DHP inhibitory site could lie between the TM 
regions, accessible from the protein-lipid interface and be allosterically affected by 
the G2’A mutation. There is however, no direct evidence for such a site, as inhibition 
by NF was unaffected by mutations at the 15' position or to non-conserved lipid-
exposed TM4 residues in the alpha1 and alpha3 subunits.  
The remaining possibility is that multiple DHP molecules may bind 
simultaneously in a region of the pore that is external to but close to the 2’ inhibitory 
site. It has recently been proposed that hydrophobic pore binding molecules of 
comparable size to NF (e.g., PTX) can bind in crevices between M2 domains in the 
GABAA receptor (Law and Lightstone, 2008). Theoretically, such a mechanism could 
permit five DHPs molecules to bind in each GlyR pore without producing block. We 
believe our results are most plausibly described by a model whereby DHP molecules 
bind in this configuration in the closed state. Channel opening would release these 
molecules into the pore where they bind to the higher affinity 2’ inhibitory site. The 
challenge is to demonstrate that DHP molecules can bind in this location in a non-
inhibiting configuration.  
 
 NF as a subunit-specific GlyR pharmacological probe 
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Inhibition of α3-containing GlyRs by the inflammatory mediator, PGE2, in spinal 
cord dorsal horn results in the disinhibition of firing in nociceptive projection neurons 
(Ahmadi et al., 2002; Harvey et al., 2004). This mechanism may underlie 
inflammation-induced hyperalgesia or allodynia (Zeilhofer, 2005; Lynch and 
Callister, 2006). Immunohistochemical and electrophysiological evidence indicates 
that α3β GlyRs are incorporated into synapses on these neurons and that 
approximately 50% of α3 subunit containing-synapses in dorsal horn neurons also co-
stain for the α1 subunit (Harvey et al., 2004).  It is not known why the α3 subunit is 
strongly expressed in these neurons, but is sparsely distributed throughout the 
remainder of the spinal cord. Investigation of the kinetic properties, sub-cellular 
distributions and relative contributions to the net glycinergic synaptic current by α1- 
and α3-containing GlyRs may help explain their presence and could provide 
important insights into pain processing mechanisms in the spinal cord. As NF inhibits 
α1β GlyRs at a 12-fold greater potency than it inhibits α3β GlyRs, it may be useful as 
a tool for selectively isolating α3β glycinergic mini-synaptic currents in voltage 
clamp recordings. However, as NF may inhibit voltage-gated K+ and Ca2+ channels 
(Fagni et al., 1994; Dunlap et al., 1995), it may not be useful in investigating the roles 
of α1- and α3-mediated inhibitory synaptic currents on neuronal firing properties. 
Our findings also suggest that the enormous array of DHP analogues already 
generated in attempt to find better therapies for cardiovascular disorders may provide 
a useful resource to screen for even more selective pharmacological tools.  
 
Conclusions 
We propose that the inhibitory GlyR DHP binding site is located near the 2’ 
position in the GlyR pore. The precise location of the non-inhibitory DHP site is less 
certain. Because this site must be able to coordinate multiple DHP molecules 
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simultaneously and must also lie close to the inhibitory site, we suggest the most 
likely explanation is that DHP molecules bind in between adjacent M2 domain 
helices, five per receptor, without inhibiting current flux.  As NF is a moderately 
selective inhibitor of α1β relative to α3β GlyRs, it may be useful as a 
pharmacological tool for investigating the role of synaptic GlyR isoforms in pain 
processing mechanisms in spinal nociceptive neurons and cone signal processing in 
the retina. Moreover, the differential sensitivity of NF and NC suggests that DHPs 
may be a useful compound class to screen for novel GlyR inhibitors with improved 
subunit-selectivity. 
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Figure legends 
 
Fig. 1. Glycine and PTX sensitivities of α1, α1β, α3 and α3β GlyRs. A. Examples of 
currents activated by the indicated glycine concentrations in cells expressing α3 and 
α3β GlyRs. In this and all subsequent figures, inward currents are represented as 
downward deflections and unfilled bars represent the period of glycine application. 
The listed glycine concentrations apply to both sets of traces. B. Averaged 
concentration-responses for the α1, α1β, α3 and α3β GlyRs. Mean parameters of best 
fit are given in Table 1. C. Examples of the inhibitory effects of 1 µM PTXININ on 
currents activated by EC50 glycine in cells expressing α3 and α3β GlyRs. PTXININ 
was applied for the period indicated by the filled bar. Displayed traces were recorded 
from the same two cells as shown in A. D. Averaged inhibition produced by 10 µM 
PTX or 1 µM PTXININ at each of the four indicated GlyR subtypes. A Student’s 
unpaired t-test was used to assess statistical significance, with *P < 0.05, ** P < 0.01, 
*** P < 0.001 representing significance relative to the corresponding homomeric GlyR. 
 
Fig. 2. Concentration-dependent effects of NC and NF at homomeric α1 subunit 
GlyRs. A. The left panel shows examples of the effects of increasing concentrations 
of NC on currents activated by EC20 (20 µM) and EC50 (30 µM) glycine in different 
cells. Note that potentiation is seen only on EC20 responses. The right panel shows the 
potentiating concentration-response (unfilled circles) averaged from 11 cells recorded 
at the EC20 glycine concentration. The inhibitory concentration-response, averaged 
from four cells at EC50 glycine, is shown as filled squares.  Parameters of best fit to 
the inhibitory concentration-response are given in Table 2. No attempt was made to fit 
the potentiating concentration-response. B. The left panel shows examples of the 
effects of increasing concentrations of NF on currents activated by EC50 (30 µM) 
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glycine. The right panel shows the concentration-response averaged from four cells. 
Parameters of best fit to the Hill equation are given in Table 2. 
 
Fig. 3. Glycine concentration-dependence and voltage-dependence of DHP inhibition 
at homomeric α1 subunit GlyRs. A. Effects of 10 µM NF and 30 µM NC on currents 
activated by EC20 (20 µM), EC50 (30 µM) and EC100 (2 mM) glycine averaged from 
five cells. There was no significant glycine-dependence for either compound. B. 
Averaged percentage inhibition induced by 10 µM NF and 30 µM NC on currents 
activated by EC50 glycine at -80, -20 and +40 mV.  Results represent the average of 
five cells. There was no significant voltage-dependence for either compound. 
 
Fig. 4. Use-dependence of DHP inhibition at homomeric α1 subunit GlyRs. A. NF 
was applied at a concentration of 10 µM and glycine was applied at 2 mM using four 
different experimental protocols as indicated. All displayed traces were recorded from 
the same cell. The horizontal lines represent the closed state (the upper-most line), the 
NF-inibited state and the open state (lower-most line), respectively. B. The onset of 
the NF inhibitory response under all four experimental conditions shown in A 
(labelled 1 - 4) are shown normalised, expanded and superimposed. Traces 1 and 2 are 
displayed as thick lines and traces 3 and 4 as thin lines. C. Exponential fits to the 
onset of the NF inhibitory response, averaged from three cells, for each of the four 
experimental conditions shown in A. D. Similar experiment to C using 30 µM NC in 
place of NF. 
 
Fig. 5. Characterisation of the ‘non-inhibiting’ binding site on homomeric α1 GlyRs. 
A. Examples of the effects of 30 s applications of 0.3, 1, 10 and 30 µM NF in the 
closed state. The effect of a 60 s application of 0.3 µM NF is also shown. A 2 mM 
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concentration of glycine was used to activate the channels to observe the subsequent 
response. Regular 2 mM glycine controls are also applied. B. The onset of the NF 
inhibitory response for each experimental condition shown in A (labelled 1 – 5) are 
shown normalised, expanded and superimposed. Trace 2 is displayed as a dashed line. 
C. Time constants fitted to the onset of the NF inhibitory response, averaged from 
four cells, as a function of NF concentration. D. Averaged peak currents (triangles) 
and minimum currents (circles) seen upon application of glycine after a 30 s pre-
application of the indicated NF concentration in the closed state. The minimum 
currents (circles) were normalised to current magnitudes measured at the same time 
point in the control traces, to take account of desensitisation. The NF inhibitory 
concentration-response curve, reproduced from Fig. 3D, is included for comparison. 
E. Examples of the effects of 30 s applications of 30 µM NF in the closed state, 
followed by a varying ‘washout’ period (0, 2, 5 and 30 s) in control solution before 
the application of 2 mM glycine. Regular 2 mM glycine controls are also applied. F. 
The onset of the NF inhibitory response for each experimental condition shown in A 
(labelled I – V) are shown normalised, expanded and superimposed. The two control 
traces labelled V are displayed as dashed lines, although traces IV and V overlap. G. 
Time constants fitted to the onset of the NF inhibitory response, averaged from three 
cells, plotted as a function of the NF washout time. The column labelled ‘no NF’ 
corresponds to trace V which was recorded in the absence of NF pre-exposure. H. 
This shows the same data as in G normalised to the maximum (no NF) time constant 
in each cell. It shows that the mean NF half recovery time was between 5 and 30 s at 
the non-inhibiting site. 
 
Fig. 6. Sensitivity of α1, α1β, α3, and α3β GlyRs to inhibition by NF and NC. A. 
Examples of the effects of 10 µM NF and 30 µM NC on EC50 glycine currents in α1 
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and α3 GlyRs. We selected an α1-expressing cell in which the NC potentiating 
response had run down. B. Averaged concentration-response curves for NF at each of 
the four receptor subtypes. B. Averaged concentration-response curves for NC at each 
of the four receptor subtypes. All averaged IC50 and nH values are presented in Table 
2. 
 
Fig. 7. Investigation into the molecular determinants of DHP inhibition. A. Sequence 
alignment of the α1, α3 and β subunit M2 domains. Non-conserved residues at the 
pore-lining 2’ and 6’ positions are shown in bold. B. Averaged concentration-
responses for NF and NC at the α1G2’Aβ GlyR. Parameters of best fit are displayed in 
Table 2. The curve fits for the respective α1β and α3β concentration-responses are 
included for comparison. C. The left and right panels show the averaged 
concentration-responses for NF and NC, respectively, at the α1T6’A, α1T6’S, α1T6’F and 
α1T6’V GlyRs. Parameters of best fit are displayed in Table 2. The inhibitory 
concentration-response curve fits for NF and NC at the α1GlyR are included for 
comparison.  
 
Fig. 8.  Sequence alignment of the M4 and C-terminal tail regions of the α1 and α3 
subunits.  Non-conserved residues are shown in bold. Residues mutated in this study 
are highlighted in grey. The dashed line represents the M4 α-helical region with bold 
dashes representing the membrane embedded portion, according to the model of 
Unwin (Unwin, 2005). The intracellular and extracellular limits of the M4 α-helix are 
denoted as ‘in’ and ‘out’, respectively. K389 was not tested as it was considered too 
distant from the extracellular membrane surface to represent a likely DHP binding 
site.
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Table 1. Glycine activation properties of all GlyRs employed in this study. 
 
 
 
*P<0.05, **P<0.01 and ***P<0.001 by unpaired Student’s t-test relative to α1 GlyR. 
 #P<0.05 and ###P<0.001 by unpaired Student’s t-test relative to α3 GlyR. 
α3N430Δ/D431Δ  refers to the α3 GlyR with the last two residues of C-terminus removed  
α3α1-M4 refers to the α3 GlyR with its M4 and C-terminal domains replaced by the 
corresponding part of α1 GlyR. 
 
 
 
 
 
 
GlyR EC50 nH n 
α1 30 ± 2 1.7 ± 0.2 5 
α1β 21 ± 1 2.0 ± 0.1 4 
α3 309 ± 19*** 2.0 ± 0.1 6 
α3β 246 ± 13*** 1.6 ± 0.1 3 
α1G2’A 22 ± 3 1.9 ± 0.3 5 
α1G2’Aβ 19 ± 5 1.7 ± 0.1 3 
α1G2’P 147 ± 27** 2.5 ± 0.3 5 
α1T6’A 1.4 ± 0.3*** 1.1 ± 0.2 8 
α1T6’S 1.1 ± 0.2*** 1.1 ± 0.3 4 
α1T6’F 6.4 ± 1.1*** 1.5 ± 0.1 6 
α1T6’V 610 ± 200* 0.8 ± 0.1 4 
α1I393A/G394A 61 ± 6** 2.5 ± 0.2 6 
α1M397A 37 ± 6 2.3 ± 0.3 4 
α1M404A 38 ± 6 2.2 ± 0.3 4 
α1R415A 49 ± 8 2.0 ± 0.1 6 
α1H419A 144 ± 25** 1.7 ± 0.1 5 
α1N420A 96 ± 8*** 2.4 ± 0.1 3 
α3Q430Δ/D431Δ 381 ± 20***# 1.7 ± 0.2 4 
α3α1-M4 123 ± 13***### 1.4 ± 0.1 5 
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Table 2. IC50 and nH values for NF and NC at wild type and mutant GlyRs 
 
GlyR 
 
[Glycine] 
(µM) 
NF NC 
 
IC50 (µM) 
 
nH 
 
n 
 
IC50 (µM) 
 
nH 
 
n 
α1 30 3.3 ± 1.5 0.54 ± 0.04 5 10.6 ± 6.0 0.70 ± 0.11 4 
α1β 30 1.2 ± 0.7 0.54 ± 0.12 4 5.8 ± 2.3 0.77 ± 0.08 5 
α3 300 29.2 ± 
3.3*** 
0.79 ± 0.11 4 30.0 ± 9.5 1.07 ± 0.17 5 
α3β 300 13.7 ± 1.9** 0.65 ± 0.08 3 11.4 ± 2.2 0.66 ± 0.06 3 
α1G2’A 30 >100  5 >100  5 
α1G2’P 150 >100  5 >100  5 
α1G2’Aβ 30 32.0 ± 7.2** 1.09 ± 0.15 3 24.0 ± 2.8 0.75 ± 0.05 6 
α1T6’A 1 3.9 ± 1.5 0.62 ± 0.04 4 3.0 ± 0.9 1.25 ± 0.21 4 
α1T6’S 1 5.6 ± 2.6 0.74 ± 0.10 5 8.7 ± 2.2 0.78 ± 0.12 5 
α1T6’F 5 4.5 ± 1.6 0.52 ± 0.05 6 15.4 ± 6.2 0.50 ± 0.03 3 
α1T6’V 600 1.4 ± 0.3 0.70 ± 0.13 4 9.2 ± 1.8 1.02 ± 0.11 4 
[Glycine] refers to the EC50 glycine concentration used to activate the currents in 
order to measure NF and NC inhibitory concentration-responses. 
Asterisks represent significance relative to α1 GlyR values by unpaired Student’s t-
test. * P<0.05, **P<0.01, ***P<0.001 
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Table 3. NF sensitivity of wild type and M4 mutant GlyRs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*P<0.05 and **P<0.01 by unpaired Student’s t-test relative to α1 GlyR.  
[Glycine] refers to the EC50 glycine concentration used to activate the currents in 
order to measure NF inhibitory potency. 
 
 
 
 
 
GlyR [Glycine]  EC50 (µM) 
% current  remaining in the 
presence of 10 µM NF n 
α1 30 33.9 ± 8.7 4 
α3 300 68.2 ± 1.9** 4 
α1I393A/G394A 60 28.5 ± 7.8 4 
α1M397A 40 24.6 ± 6.1 4 
α1M404A 40 18.5 ± 5.9 5 
α1R415A 40 25.4 ± 4.8 4 
α1H419A 130 20.8 ± 3.6 3 
α1N420A 90 16.2 ± 2.2 4 
α3N430Δ/D431Δ 350 55.3 ± 6.0 3 
α3α1-M4 120 74.1 ± 5.7* 3 
